1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Ceftibuten Capsules Formulation

Manufacturer or supplier’s details

Company: MSD
Address: 199 Wenhai North Road
             HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance: powder
Colour: No data available
Odour: No data available

Harmful if inhaled. May cause allergy or asthma symptoms or breathing difficulties if inhaled.

GHS Classification

Acute toxicity (Inhalation): Category 4
Respiratory sensitisation: Category 1

GHS label elements

Hazard pictograms:

Signal word: Danger
Hazard statements:
H332 Harmful if inhaled.
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary statements:

Prevention:
P261 Avoid breathing dust.
P271 Use only outdoors or in a well-ventilated area.
P284 Wear respiratory protection.
Ceftibuten Capsules Formulation

Response:
P304 + P340 + P312 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Call a POISON CENTER/doctor if you feel unwell.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/doctor.

Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards
Not classified based on available information.

Health hazards
Harmful if inhaled. May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftibuten</td>
<td>CAS-No. 97519-39-6</td>
</tr>
<tr>
<td>Cellulose</td>
<td>CAS-No. 9004-34-6</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>CAS-No. 557-04-0</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.

In case of skin contact: Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact: If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed: If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed: Hazardous if inhaled. May cause allergy or asthma symptoms or breathing difficulties if inhaled. Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome). Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

**Suitable extinguishing media**: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

**Unsuitable extinguishing media**: None known.

**Specific hazards during firefighting**: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

**Hazardous combustion products**: Carbon oxides
Metal oxides

**Specific extinguishing methods**: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

**Special protective equipment for firefighters**: In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

**Personal precautions, protective equipment and emergency procedures**: Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

**Environmental precautions**: Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

**Methods and materials for containment and cleaning up**: Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces...
with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Handling
Technical measures: Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation: If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling: Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals should consult their physician regarding working with respiratory irritants or sensitisers.
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact: Oxidizing agents

Storage
Conditions for safe storage: Keep in properly labelled containers.
Keep tightly closed.
Keep in a cool, well-ventilated place.
Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
Strong oxidizing agents

Packaging material: Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
</table>

4 / 15
Ceftibuten Capsules Formulation

<table>
<thead>
<tr>
<th>Substance</th>
<th>Code</th>
<th>Exposure Form</th>
<th>Permissible Concentration</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ceftibuten</td>
<td>97519-39-6</td>
<td>TWA</td>
<td>1 mg/m³ (OEB 1)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>0.1 mg/100 cm²</td>
</tr>
<tr>
<td>Cellulose</td>
<td>9004-34-6</td>
<td>PC-TWA</td>
<td>10 mg/m³</td>
<td>GBZ 2.1-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Magnesium stearate</td>
<td>557-04-0</td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
</tbody>
</table>

Engineering measures: Use feasible engineering controls to minimize exposure to compound. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment
- Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type
  - Eye/face protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Skin and body protection: Work uniform or laboratory coat.
- Hand protection: Chemical-resistant gloves
- Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES
- Appearance: powder
- Colour: No data available
Odour : No data available
Odour Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : Not applicable
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapour pressure : No data available
Relative vapour density : No data available
Density : No data available
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available
10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.
Incompatible materials: Oxidizing agents
Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes: Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity: Harmful if inhaled.

Product:
Acute inhalation toxicity: Acute toxicity estimate: 2.25 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: Calculation method

Components:

Ceftibuten:
Acute oral toxicity: LD50 (Rat): 10,000 mg/kg
LD50 (Dog): 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 3.94 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Cellulose:
Acute oral toxicity: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity: LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg

Magnesium stearate:
Acute oral toxicity: LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity: LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation
Not classified based on available information.

**Components:**

**Ceftibuten:**
Species: Rabbit
Result: No skin irritation

**Magnesium stearate:**
Species: Rabbit
Result: No skin irritation
Remarks: Based on data from similar materials

Serious eye damage/eye irritation
Not classified based on available information.

**Components:**

**Ceftibuten:**
Species: Rabbit
Result: No eye irritation

**Magnesium stearate:**
Species: Rabbit
Result: No eye irritation
Remarks: Based on data from similar materials

Respiratory or skin sensitisation

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:**

**Ceftibuten:**
Assessment: Probability or evidence of high respiratory sensitisation rate in humans
Magnesium stearate:
- Test Type: Maximisation Test
- Exposure routes: Skin contact
- Species: Guinea pig
- Method: OECD Test Guideline 406
- Result: negative
- Remarks: Based on data from similar materials

Germ cell mutagenicity
Not classified based on available information.

Components:

Ceftibuten:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: Chromosome aberration test in vitro
  - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

- Genotoxicity in vivo:
  - Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)
  - Species: Mouse
  - Application Route: Intraperitoneal injection
  - Result: negative

Cellulose:
- Genotoxicity in vitro:
  - Test Type: Bacterial reverse mutation assay (AMES)
  - Result: negative
  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative

- Genotoxicity in vivo:
  - Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
  - Species: Mouse
  - Application Route: Ingestion
  - Result: negative

Magnesium stearate:
- Genotoxicity in vitro:
  - Test Type: In vitro mammalian cell gene mutation test
  - Result: negative
  - Remarks: Based on data from similar materials
  - Test Type: Chromosome aberration test in vitro
  - Method: OECD Test Guideline 473
  - Result: negative
  - Remarks: Based on data from similar materials
## Ceftibuten Capsules Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue: 2019/09/13</th>
<th>Date of first issue: 2016/03/15</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9</td>
<td>2020/03/23</td>
<td>559516-00011</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

### Carcinogenicity
Not classified based on available information.

### Components:

#### Cellulose:

<table>
<thead>
<tr>
<th>Species</th>
<th>Application Route</th>
<th>Exposure time</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Ingestion</td>
<td>72 weeks</td>
<td>negative</td>
</tr>
</tbody>
</table>

### Reproductive toxicity
Not classified based on available information.

### Components:

#### Ceftibuten:

- **Effects on fertility**
  - Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Oral
  - Fertility: NOAEL: 2,000 mg/kg body weight
  - Result: No effects on fertility

- **Effects on foetal development**
  - Test Type: Embryo-foetal development
  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: > 4,000 mg/kg body weight

  - Test Type: Embryo-foetal development
  - Species: Rabbit
  - Application Route: Oral
  - Developmental Toxicity: NOAEL: > 40 mg/kg body weight

  - Species: Rat
  - Application Route: Oral
  - Developmental Toxicity: LOAEL: >= 125 mg/kg body weight
  - Result: Reduced offspring weight gain

#### Cellulose:

- **Effects on fertility**
  - Test Type: One-generation reproduction toxicity study
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative

- **Effects on foetal development**
  - Test Type: Fertility/early embryonic development
  - Species: Rat
  - Application Route: Ingestion
  - Result: negative
Magnesium stearate:
Effects on fertility: Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative
Remarks: Based on data from similar materials

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT - single exposure
Not classified based on available information.

STOT - repeated exposure
Not classified based on available information.

Repeated dose toxicity

Components:

Ceftibuten:
Species: Rat
LOAEL: 3,000 mg/kg
Application Route: Oral
Exposure time: 3 Months
Target Organs: Gastrointestinal tract, Heart
Symptoms: No adverse effects

Species: Dog
LOAEL: 800 mg/kg
Application Route: Oral
Target Organs: Gastrointestinal tract, Heart
Symptoms: No adverse effects

Cellulose:
Species: Rat
NOAEL: >= 9,000 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Magnesium stearate:
Species: Rat
NOAEL: > 100 mg/kg
Application Route: Ingestion
Exposure time: 90 Days
Remarks: Based on data from similar materials
Ceftibuten Capsules Formulation

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Ceftibuten:
Inhalation: Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis, Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Ceftibuten:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 600 mg/l
Exposure time: 48 h
Method: FDA 4.08

Cellulose:
Toxicity to fish: LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l
Exposure time: 48 h
Remarks: Based on data from similar materials

Magnesium stearate:
Toxicity to fish: LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

Toxicity to algae/aquatic plants: EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Ceftibuten Capsules Formulation

Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms: EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Cellulose:
Biodegradability: Result: Readily biodegradable.

Magnesium stearate:
Biodegradability: Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Magnesium stearate:
Partition coefficient: n-octanol/water: log Pow: > 4

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good
## Ceftibuten Capsules Formulation

**Version** 2.9  
**Revision Date:** 2020/03/23  
**SDS Number:** 559516-00011  
**Date of last issue:** 2019/09/13  
**Date of first issue:** 2016/03/15

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

### National Regulations

| GB 6944/12268 | Not regulated as a dangerous good |

### Special precautions for user
Not applicable

### 15. REGULATORY INFORMATION

**National regulatory information**

**Law on the Prevention and Control of Occupational Diseases**

The components of this product are reported in the following inventories:

- **AICS**: not determined
- **DSL**: not determined
- **IECSC**: not determined

### 16. OTHER INFORMATION

**Further information**


Date format: yyyy/mm/dd

**Full text of other abbreviations**

- **ACGIH**: USA. ACGIH Threshold Limit Values (TLV)
- **GBZ 2.1-2007**: Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.
- **ACGIH / TWA**: 8-hour, time-weighted average
- **GBZ 2.1-2007 / PC-TWA**: Permissible concentration - time weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemi-
SAFETY DATA SHEET
generated according to GB/T 16483 and GB/T 17519

Ceftibuten Capsules Formulation

Version: 2.9
Revision Date: 2020/03/23
SDS Number: 559516-00011
Date of last issue: 2019/09/13
Date of first issue: 2016/03/15

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

CN / EN